Protein Biomarker Detection Service

Protein biomarkers are biochemical indicators that can mark alterations or possible changes in the structure or function of systems, organs, tissues, cells and sub-cells, and are crucial in the early diagnosis and screening of diseases.

Early detection of protein biomarkers is essential for disease diagnosis. As a professional analyte detection company, CD BioSciences is committed to providing efficient protein biomarker detection service.

Protein Biomarker Detection by CRIPSR-Cas System

CRISPR-Cas technology originated from the adaptive immune system of bacteria and archaea and has gained great popularity in recent years due to its success in gene editing. CRISPR-Cas-driven biosensors have attracted great research interest due to their high precision, good specificity, fast reaction time and good integrity. Currently, CRISPR technology has promising applications not only for nucleic acid testing, but also for protein biomarker detection.

CRISPR-Cas9	CRISPR-Cas13
A new peptide display platform, PICASSO, has been developed using CRISPR-Cas9 technology. Using this platform, DNA molecules can be placed at specific locations on a surface, and each protein in the mixture then self-assembles to the corresponding DNA sequence, and the resulting DNA template protein microarrays allow you to quickly identify antibodies in clinical samples, or to identify any protein of interest to you.	Based on the signal amplification capability of the CRISPR-Cas system, researchers have developed an enzyme-linked immunosorbent assay using CRISPR-Cas13a as a signal amplification strategy, referred to as CLISA. The method allows for the detection of multiple protein biomarkers for disease diagnosis. The CARPID detection uses the CRISPR-Cas13d system to specifically tract a BASU biotin transferase fused to it to the vicinity of lncRNA in living cells, biotinylating the neighboring protein, which is subsequently separated using streptavidin-coupled magnetic beads, followed by label-free quantitative comparative analysis of the separated protein by mass spectrometry to confirm the binding of lncRNA proteins.

CRISPR-Cas9

CRISPR-Cas13

A new peptide display platform, PICASSO, has been developed using CRISPR-Cas9 technology. Using this platform, DNA molecules can be placed at specific locations on a surface, and each protein in the mixture then self-assembles to the corresponding DNA sequence, and the resulting DNA template protein microarrays allow you to quickly identify antibodies in clinical samples, or to identify any protein of interest to you.

Based on the signal amplification capability of the CRISPR-Cas system, researchers have developed an enzyme-linked immunosorbent assay using CRISPR-Cas13a as a signal amplification strategy, referred to as CLISA. The method allows for the detection of multiple protein biomarkers for disease diagnosis.

The CARPID detection uses the CRISPR-Cas13d system to specifically tract a BASU biotin transferase fused to it to the vicinity of lncRNA in living cells, biotinylating the neighboring protein, which is subsequently separated using streptavidin-coupled magnetic beads, followed by label-free quantitative comparative analysis of the separated protein by mass spectrometry to confirm the binding of lncRNA proteins.

Our Services

Utilizing the CRISPR-Cas system's ability to specifically identify and cleave nucleic acid sequences, CD BioSciences offer highly sensitive protein biomarker detection service. In addition, we also provide detection services for nucleic acids, metal ions and small molecules.

Our DeteCas™ platform can detect protein biomarkers for different diseases, including but not limited to the followings.

Cancer Protein Biomarker Detection Service

Neurological Diseases Protein Biomarker Detection Service

Cardiovascular Diseases Protein Biomarker Detection Service

Immunological Diseases Protein Biomarker Detection Service

Advantages of Our Service

High sensitivity for detection of low concentration substances.
High detection efficiency using an optimized CRISPR-Cas system.
Different detection solutions to meet different research needs.
Regular reporting of experimental progress.

Process of Our Service

CD BioSciences provides affordable, qualified and hassle-free protein biomarker detection service to our global clients. We guarantee on-time delivery of results. We are available to you 24 hours a day, so please feel free to contact us.

References

Xie, S.Y., et al. Advancing sensing technology with CRISPR: From the detection of nucleic acids to a broad range of analytes-A review. Analytica Chimica Acta. 2021, 338848.
Chen, Q., et al. CRISPR/Cas13a Signal Amplification Linked Immunosorbent Assay for Femtomolar Protein Detection. Analytical Chemistry. 2020, 1(92): 573-577.
Karl, W.B., et al. CRISPR-based peptide library display and programmable microarray self-assembly for rapid quantitative protein binding assays. Molecular Cell. 2021, 7(27): 3650-3658.
Gong, S.H., et al. CRISPR/Cas-Based In Vitro Diagnostic Platforms for Cancer Biomarker Detection. Analytical Chemistry. 2021, 93(35): 11899-11909.

For research use only. Not intended for any clinical use.